Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open-label, Controlled Extension Study to Evaluate the Rebound Effect and Long-term Safety of Software SAT-001 for the Inhibition of Myopia Progression and Treatment in Pediatric Patients With Myopia

NCT06742268 is registered in ClinicalTrials.gov with S-Alpha Therapeutics, Inc. as lead sponsor.

NCT NCT06742268
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06742268 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open-label, Controlled Extension Study to Evaluate the Rebound Effect and Long-term Safety of Software SAT-001 for the Inhibition of Myopia Progression and Treatment in Pediatric Patients With Myopia
Lead sponsor
S-Alpha Therapeutics, Inc.
Phase
Observational
Overall status
Recruiting
Start date
December 16, 2024
Completion date
July 30, 2026
Enrollment
40 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

myopia